Ranitidine 150mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Ranitidine hydrochloride

Available from:

Flamingo Pharma (UK) Ltd

ATC code:

A02BA02

INN (International Name):

Ranitidine hydrochloride

Dosage:

150mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 01030100; GTIN: 5060464501944

Patient Information leaflet

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING
THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION
FOR YOU.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or
pharmacist.
• This medicine has been prescribed for you only. Do not
pass it on to others. It may harm them, even if their signs
of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this
leaflet. See section 4.
DO NOT TAKE RANITIDINE FILM-COATED TABLETS:
• if you are allergic to ranitidine or any of the other
ingredients of this medicine (listed in section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Ranitidine
Film-coated Tablets if:
• you have stomach cancer
• you have kidney problems. You will need to take a different
amount of Ranitidine Film-coated Tablets
• you have had stomach ulcers before and you are taking
Non-Steroidal Anti-Inflammatory (NSAID) medicines
• you have a rare condition called acute porphyria
• you are over 65 years old
• you have lung disease
• you are diabetic
• you have any problems with your immune system.
If you are not sure, talk to your doctor or pharmacist before
taking Ranitidine Film-coated Tablets.
If you are not sure if any of the above applies to you,
talk to your doctor or pharmacist before using this
medicine.
PACKAGE LEAFLET: INFORMATION FOR THE USER
RANITIDINE 150 MG FILM-COATED TABLETS
RANITIDINE 300 MG FILM-COATED TABLETS
RANITIDINE HYDROCHLORIDE
WHAT IS IN THIS LEAFLET:
1. What Ranitidine Film-coated Tablet is and what it is
used for
2. What you need to know before you take Ranitidine
Film-coated Tablets
3. How to take Ranitidine Film-coated Tablets
4. Possible side effects
5. How to store Ranitidine Film-coated Tablets
6. Contents of the pack and other information
1. WHAT RANITIDINE FILM-COATED TABLET IS AND WHAT IT IS USED FOR
Ranitidine Film-coated Tablet contains a medicine called

Summary of Product characteristics

OBJECT 1
RANITIDINE 150MG TABLETS
Summary of Product Characteristics Updated 08-Apr-2020 | Flamingo
Pharma (UK) Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Ranitidine 150 mg Film-coated Tablets
2. Qualitative and quantitative composition
Each film-coated tablet contains 168 mg of Ranitidine hydrochloride
equivalent to 150 mg of Ranitidine.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated Tablet
Brown, round shaped, biconvex, beveled edge film coated tablets with
breakline on one side and plain on
other side.
The tablet can be divided into equal doses.
4. Clinical particulars
4.1 Therapeutic indications
Adults
Duodenal ulcer and benign gastric ulcer, including that associated
with non-steroidal anti-inflammatory
agents.
Prevention of non-steroidal anti-inflammatory drug (NSAID) (including
aspirin) associated duodenal
ulcers, especially in patients with a history of peptic ulcer disease.
Treatment of duodenal ulcers associated wi